Conditional Deletion of Jak2 Reveals an Essential Role in Hematopoiesis throughout Mouse Ontogeny: Implications for Jak2 Inhibition in Humans

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Park, Sung O ^a   Wamsley, Heather L ^b   Bae, Kyungmi ^a   Hu, Zhongbo ^a   Li, Xiaomiao ^a   Choe, Se woon ^a   Slayton, William B ^a   Oh, S Paul ^a   Wagner, Kay Uwe ^c   Sayeski, Peter P ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b University of Florida   (United States)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

JANUS KINASE 2; TAMOXIFEN;

ADULT ANIMAL; ADULTHOOD; ANEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL LINEAGE; CONTROLLED STUDY; EMBRYO; EMBRYO DEATH; ERYTHROCYTE STRUCTURE; ERYTHROPOIESIS; FUNCTIONS OF THE HEMIC, LYMPHATIC AND RETICULOENDOTHELIAL SYSTEMS; GENE DELETION; GENE FUNCTION; GESTATIONAL AGE; GRANULOPOIESIS; HEMATOPOIESIS; JANUS KINASE 2 GENE; LYMPHOPOIESIS; MONOCYTOPOIESIS; MOUSE; NONHUMAN; NULL ALLELE; ONTOGENY; PERINATAL PERIOD; PHENOTYPIC VARIATION; SPLEEN DISEASE; SURVIVAL RATE; THROMBOCYTOPENIA; THROMBOCYTOPOIESIS;

AGING; ANEMIA; ANIMALS; ANIMALS, NEWBORN; BLOOD CELL COUNT; EMBRYO LOSS; EMBRYONIC DEVELOPMENT; FEMALE; GENE DELETION; GTP-BINDING PROTEINS; HEMATOPOIESIS; HEMATOPOIETIC STEM CELLS; HUMANS; INTERFERON REGULATORY FACTOR-1; JANUS KINASE 2; LYMPHOCYTES; MICE; MICE, KNOCKOUT; MYELOID PROGENITOR CELLS; ORGAN SPECIFICITY; PREGNANCY; SPLEEN; SURVIVAL ANALYSIS; TAMOXIFEN;

ANIMALIA; MUS;

EID: 84875424883     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0059675     Document Type: Article

References (38)

1. Tsygankov A, Bolen J, (1993) The Src family of tyrosine protein kinases in hemopoietic signal transduction. Stem Cell 11: 371-380.
2. Corey SJ, Anderson SM, (1999) Src-related protein tyrosine kinases in hematopoiesis. Blood 93: 1-14.
3. Rane SG, Reddy EP, (2002) JAKs, STATs and Src kinases in hematopoiesis. Oncogene 21: 3334-3358.
4. Khwaja A, (2006) The role of Janus kinases in haemopoiesis and haematological malignancy. Br J Haematol. 134: 366-384.
5. Harpur AG, Andres AC, Ziemiecki A, Aston RR, Wilks AF, (1992) JAK2, a third member of the JAK family of protein tyrosine kinases. Oncogene 7: 1347-1353.
6. Witthuhn BA, Quelle FW, Silvennoinen O, Yi T, Tang B, et al. (1993) JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin. Cell 74: 227-236.
7. Argetsinger LS, Campbell GS, Yang X, Witthuhn BA, Silvennoinen O, et al. (1993) Identification of JAK2 as a growth hormone receptor-associated tyrosine kinase. Cell 74: 237-244.
8. Parganas E, Wang D, Stravopodis D, Topham DJ, Marine JC, et al. (1998) Jak2 is essential for signaling through a variety of cytokine receptors. Cell 93: 385-395.
9. Neubauer H, Cumano A, Müller M, Wu H, Huffstadt U, et al. (1998) Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis. Cell 93: 397-409.
10. James C, Ugo V, Le Couédic JP, Staerk J, Delhommeau F, et al. (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434: 1144-1148.
11. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, et al. (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352: 1779-1790.
12. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, et al. (2005) Cancer Genome Project. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365: 1054-1061.
13. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, et al. (2005) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7: 387-397.
14. Zhao R, Xing S, Li Z, Fu X, Li Q, et al. (2005) Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem 280: 22788-22792.
15. Tefferi A, Pardanani A, (2011) Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis. Mayo Clin Proc. 86: 1188-1191.
16. Tefferi A, Litzow MR, Pardanani A, (2011) Long-term outcome of treatment with ruxolitinib in myelofibrosis. N Engl J Med 365: 1455-1457.
17. Mascarenhas J, Hoffman R, (2012) Ruxolitinib: the first FDA approved therapy for the treatment of myelofibrosis. Clin Cancer Res 18: 3008-3014.
18. Tefferi A, (2012) Challenges facing JAK inhibitor therapy for myeloproliferative neoplasms. N Engl J Med 366: 844-846.
19. Tefferi A, Pardanani A, (2011) JAK inhibitors in myeloproliferative neoplasms: rationale, current data and perspective. Blood Rev. 25: 229-237.
20. Sandberg EM, Wallace TA, Godeny MD, VonDerLinden D, Sayeski PP, (2004) Jak2 tyrosine kinase: a true Jak of all trades? Cell Biochem Biophys 41: 207-232.
21. Krempler A, Qi Y, Triplett AA, Zhu J, Rui H, et al. (2004) Generation of a conditional knockout allele for the Janus kinase 2 (Jak2) gene in mice. Genesis 40: 52-57.
22. Lan ZJ, Xu X, Cooney AJ, (2004) Differential oocyte-specific expression of Cre recombinase activity in GDF-9-iCre, Zp3cre, and Msx2Cre transgenic mice. Biol Reprod 71: 1469-1474.
23. Soriano P, (1999) Generalized lacZ expression with the ROSA26 Cre reporter strain. Nat Genetics 21: 70-71.
24. Yoon SY, Tefferi A, Li CY, (2001) Bone marrow stromal cell distribution of basic fibroblast growth factor in chronic myeloid disorders. Haematologica 86: 52-57.
25. Sharma Y, Astle CM, Harrison DE, (2007) Heterozygous kit mutants with little or no apparent anemia exhibit large defects in overall hematopoietic stem cell function. Exp Hematol 35: 214-220.
26. Li XM, Hu Z, Zafar AB, Jorgensen ML, Bungert J, et al. (2010) Intrinsic and extrinsic effects of mafG deficiency on hematopoietic recovery following bone marrow transplant. Exp Hematol 38: 1251-1260.
27. Agosti V, Corbacioglu S, Ehlers I, Waskow C, Sommer G, et al. (2004) Critical role for Kit-mediated Src kinase but not PI 3-kinase signaling in pro T and pro B cell development. J Exp Med 199: 867-878.
28. Lannutti BJ, Minear J, Blake N, Drachman JG, (2006) Increased megakaryocytopoiesis in Lyn-deficient mice. Oncogene 25: 3316-3324.
29. Karur VG, Lowell CA, Besmer P, Agosti V, Wojchowski DM, (2006) Lyn kinase promotes erythroblast expansion and late-stage development. Blood 108: 1524-1532.
30. Xiao W, Hong H, Kawakami Y, Lowell CA, Kawakami T, (2008) Regulation of myeloproliferation and M2 macrophage programming in mice by Lyn/Hck, SHIP, and Stat5. J Clin Invest 118: 924-934.
31. Mazharian A, Thomas SG, Dhanjal TS, Buckley CD, Watson SP, (2010) Critical role of Src-Syk-PLCγ2 signaling in megakaryocyte migration and thrombopoiesis. Blood 116: 793-800.
32. Neria F, Castilla MA, Sanchez RF, Gonzalez Pacheco FR, Deudero JJ, et al. (2009) Inhibition of JAK2 protects renal endothelial and epithelial cells from oxidative stress and cyclosporin A toxicity. Kidney Int 75: 227-234.
33. Guilluy C, Brégeon J, Toumaniantz G, Rolli-Derkinderen M, Retailleau K, et al. (2010) The Rho exchange factor Arhgef1 mediates the effects of angiotensin II on vascular tone and blood pressure. Nat Med 16: 183-190.
34. Booz GW, Day JN, Baker KM, (2002) Interplay between the cardiac renin angiotensin system and JAK-STAT signaling: role in cardiac hypertrophy, ischemia/reperfusion dysfunction, and heart failure. J Mol Cell Cardiol 34: 1443-1453.
35. Huang H, Kong D, Byun KH, Ye C, Koda S, et al. (2012) Rho-kinase regulates energy balance by targeting hypothalamic leptin receptor signaling. Nat Neurosci 15: 1391-1398.
36. Frenzel K, Wallace TA, McDoom I, Xiao HD, Capecchi MR, et al. (2006) A functional Jak2 tyrosine kinase domain is essential for mouse development. Exp Cell Res 312: 2735-2744.
37. Tefferi A, (2012) JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths. Blood 119: 2721-2730.
38. Hart S, Goh KC, Novotny-Diermayr V, Hu CY, Hentze H, et al. (2011) SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies. Leukemia 25: 1751-1759.